Pharmaceutical Technology on MSN7d
Sanofi’s Qfitlia approved by FDA as first haemophilia therapy for all patientsDespite a haemophilia market bustling with rivals, Qfitlia’s broad label and favourable dosing regimen could give it an upper ...
Health and Me on MSN5d
FDA Approves Qfitlia For Hemophilia PatientsThe approval came on the basis of two randomized clinical trials that had 177 adult and pediatric male patients with either ...
The U.S. Food and Drug Administration has approved Sanofi's Qfitlia (fitusiran) for routine prophylaxis to prevent or reduce ...
Sanofi’s treatment for hemophilia that can be administered as infrequently as once every other month, was approved by the US ...
Zacks Investment Research on MSN6d
SNY Gets FDA Nod for First Ever Hemophilia Drug in the United StatesSanofi SNY and partner, Alnylam Pharmaceuticals ALNY, announced that the FDA has approved Qfitlia (fitusiran) as the first ...
The FDA has recently approved two new prophylactic treatments for people with hemophilia who develop antibodies to clotting ...
"Today's approval of Qfitlia is significant for patients with hemophilia because it can be administered less frequently than other existing options," said Tanya Wroblewski, MD, deputy director of ...
The agreement with the GKV-Spitzenverband – the national association of statutory health insurance funds – means that Hemgenix (etranacogene dezaparvovec) can now be reimbursed across Germany's health ...
Fitusiran is a small interference RNA therapeutic designed to prevent bleeds in patients with hemophilia A or B by lowering antithrombin.
Unlike other hemophilia therapies, Qfitlia is indicated for both hemophilia A and B, and can be given in patients regardless ...
Qfitlia approved as the first therapy in the US to treat hemophilia A or B with or without inhibitors Qfitlia (fitusiran), the first ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback